FAIRFIELD, N.J.--(BUSINESS WIRE)--Nov. 3, 2006--Unigene
Laboratories, Inc.'s (OTCBB: UGNE) President and CEO, Dr. Warren Levy,
will speak at the 8th Annual Rodman and Renshaw Healthcare Conference
on Wednesday, November 8 at 11:00 AM EST. Dr. Levy will present
information on Unigene's products and collaborations. The conference
will be held at The New York Palace Hotel in New York City on November
6-8.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing
on the oral and nasal delivery of large-market peptide drugs. Due to
the size of the worldwide osteoporosis market, Unigene is targeting
its initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
August 2005. Unigene has licensed the U.S. rights for Fortical to
Upsher-Smith Laboratories, worldwide rights for its oral PTH
technology to GlaxoSmithKline and worldwide rights for its calcitonin
manufacturing technology to Novartis. Unigene's patented oral delivery
technology has successfully delivered, in preclinical and/or clinical
trials, various peptides including calcitonin, PTH and insulin.
Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call (973) 882-0860 or visit
www.unigene.com. For information about Fortical, visit
www.fortical.com.
The presentation time is subject to change. Safe Harbor statements
under the Private Securities Litigation Reform Act of 1995: This press
release contains forward-looking statements as defined in Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements are based upon Unigene Laboratories, Inc.'s management's
current expectations, estimates, beliefs, assumptions, and projections
about Unigene's business and industry. Words such as "anticipates,"
"expects," "intends," "plans," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "potential,"
"continue," and variations of these words (or negatives of these
words) or similar expressions, are intended to identify
forward-looking statements. In addition, any statements that refer to
expectations, projections, or other characterizations of future events
or circumstances, including any underlying assumptions, are
forward-looking statements. These forward-looking statements are not
guarantees of future performance and are subject to certain risks,
uncertainties, and assumptions that are difficult to predict.
Therefore, our actual results could differ materially and adversely
from those expressed in any forward-looking statements as a result of
various risk factors. These risks and uncertainties include the risks
associated with the effect of changing economic conditions, trends in
the products markets, variations in Unigene's cash flow, market
acceptance risks, technical development risks and other risk factors
detailed in Unigene's Securities and Exchange Commission filings.
CONTACT:
The Investor Relations Group
Investor:
Damian McIntosh / Dian Griesel, Ph.D.
212-825-3210
or
Media:
Janet Vasquez, 212-825-3210
SOURCE: Unigene Laboratories, Inc.
|
